Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration

ConclusionsOur findings indicate an active, immunomodulatory mechanism for the anti-PD-1 antibody sasanlimab across different tumor types and routes of administration.Trial RegistrationClinicalTrials.gov identifier NCT02573259; registered October 2015.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research